Davis C, Javor E, Rebarber S, Rychtar J, Taylor D
PLoS One. 2024; 19(10):e0311314.
PMID: 39365771
PMC: 11452004.
DOI: 10.1371/journal.pone.0311314.
Abdullahi B, Mutiso J, Maloba F, Macharia J, Riongoita M, Gicheru M
J Trop Med. 2024; 2022:1441576.
PMID: 39263045
PMC: 11390187.
DOI: 10.1155/2022/1441576.
Li J, Liu L, Gao Z, Chuai X, Liu X, Zhang X
Infect Drug Resist. 2024; 17:3769-3775.
PMID: 39229329
PMC: 11370764.
DOI: 10.2147/IDR.S468684.
OBrien K, Kennedy G, Nyakundi H, Kitondo M, Pembee V, Biwott W
Am J Trop Med Hyg. 2024; 111(5):940-949.
PMID: 39226891
PMC: 11542538.
DOI: 10.4269/ajtmh.23-0781.
Hagos D, Kiros Y, Abdulkader M, Schallig H, Wolday D
Diagnostics (Basel). 2024; 14(2).
PMID: 38248040
PMC: 10813839.
DOI: 10.3390/diagnostics14020163.
Evaluation of a Point-of-Need Molecular Diagnostic Tool Coupled with Rapid DNA Extraction Methods for Visceral Leishmaniasis.
Ghosh P, Chowdhury R, Faisal K, Khan M, Hossain F, Rahat M
Diagnostics (Basel). 2023; 13(24).
PMID: 38132223
PMC: 10742398.
DOI: 10.3390/diagnostics13243639.
Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Kumar A, Singh V, Tiwari R, Madhukar P, Rajneesh , Kumar S
Front Immunol. 2023; 14:1236952.
PMID: 37638047
PMC: 10451093.
DOI: 10.3389/fimmu.2023.1236952.
Case Report: FDG-PET/CT findings in co-infection of visceral leishmaniasis and chronic hepatitis B.
Feng H, Dai W
Front Cell Infect Microbiol. 2023; 13:1175897.
PMID: 37325515
PMC: 10264663.
DOI: 10.3389/fcimb.2023.1175897.
Visceral Leishmaniasis Associated with HIV Coinfection in Pará, Brazil.
Camargo Junior R, Sarmento Gomes J, Correa Carvalho M, de Menezes Chalkidis H, Silva W, Sousa da Silva J
HIV AIDS (Auckl). 2023; 15:247-255.
PMID: 37255531
PMC: 10226483.
DOI: 10.2147/HIV.S400189.
Seroprevalence of Visceral Leishmaniasis in Children Up To 12 Years Old of Rural Areas from Kermanshah Province, Western Part of Iran.
Sedaghatmanesh K, Khazan H, Akhoundi B, Khazaei S, Kakooei Z, Mohebali M
Iran J Parasitol. 2023; 18(1):85-92.
PMID: 37197081
PMC: 10183451.
DOI: 10.18502/ijpa.v18i1.12384.
Structural Modelling of Platelet Activating Factor Acetyl Hydrolase in , , and : Implications on Therapeutics for Leishmaniasis, Chagas Disease, and Sleeping Sickness.
Goswami A, Koley T, Rajan M, Madhuri P, Upadhyay N, Das U
Infect Drug Resist. 2023; 16:2117-2128.
PMID: 37070125
PMC: 10105589.
DOI: 10.2147/IDR.S403411.
Challenges of using modelling evidence in the visceral leishmaniasis elimination programme in India.
Dial N, Croft S, Chapman L, Terris-Prestholt F, Medley G
PLOS Glob Public Health. 2023; 2(11):e0001049.
PMID: 36962829
PMC: 10021829.
DOI: 10.1371/journal.pgph.0001049.
The paradigm of intracellular parasite survival and drug resistance in leishmanial parasite through genome plasticity and epigenetics: Perception and future perspective.
Kamran M, Bhattacharjee R, Das S, Mukherjee S, Ali N
Front Cell Infect Microbiol. 2023; 13:1001973.
PMID: 36814446
PMC: 9939536.
DOI: 10.3389/fcimb.2023.1001973.
Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis-An updated review.
Kumar P, Kumar P, Singh N, Khajuria S, Patel R, Rajana V
Front Bioeng Biotechnol. 2023; 10:1016925.
PMID: 36588956
PMC: 9794769.
DOI: 10.3389/fbioe.2022.1016925.
Novel Selective and Low-Toxic Inhibitor of CPB2.8ΔCTE (CPB) One Important Cysteine Protease for Virulence.
Moreira V, da Silva Mela M, Dos Anjos L, Figueiredo Saraiva L, Arenas Velasquez A, Kalaba P
Biomolecules. 2022; 12(12).
PMID: 36551331
PMC: 9775234.
DOI: 10.3390/biom12121903.
Humoral and Cellular Immune Response in Asymptomatic Dogs with Visceral Leishmaniasis: A Review.
Garcia-Castro A, Egui A, Carmen Thomas M, Lopez M
Vaccines (Basel). 2022; 10(6).
PMID: 35746555
PMC: 9229064.
DOI: 10.3390/vaccines10060947.
Establish an allele-specific real-time PCR for Leishmania species identification.
Wu Y, Jiang M, Li S, Waterfield N, Yang G
Infect Dis Poverty. 2022; 11(1):60.
PMID: 35655325
PMC: 9164491.
DOI: 10.1186/s40249-022-00992-y.
Metalloprotease Gp63-Targeting Novel Glycoside Exhibits Potential Antileishmanial Activity.
Chakrabarti A, Narayana C, Joshi N, Garg S, Garg L, Ranganathan A
Front Cell Infect Microbiol. 2022; 12:803048.
PMID: 35601095
PMC: 9115111.
DOI: 10.3389/fcimb.2022.803048.
miR-548d-3p Is Up-Regulated in Human Visceral Leishmaniasis and Suppresses Parasite Growth in Macrophages.
Ramos-Sanchez E, Reis L, Souza M, Muxel S, Santos K, Lagos D
Front Cell Infect Microbiol. 2022; 12():826039.
PMID: 35265535
PMC: 8900537.
DOI: 10.3389/fcimb.2022.826039.
Identification and Quantification, Metabolism and Pharmacokinetics, Pharmacological Activities, and Botanical Preparations of Protopine: A Review.
Huang W, Kong L, Cao Y, Yan L
Molecules. 2022; 27(1).
PMID: 35011447
PMC: 8746401.
DOI: 10.3390/molecules27010215.